PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The safety and effectiveness of 2-liter polyethylene glycol plus ascorbic acid in patients with liver cirrhosis: A retrospective observational study.

Abstract The safety of bowel-cleansing agents is an important issue in clinical practice, especially in patients with chronic diseases. Although the safety and efficacy of polyethylene glycol (PEG) has been investigated in many studies, few studies on PEG plus ascorbic acid exist. In this study, we compared the safety of 2 bowel-cleansing agents for patients with liver cirrhosis: 2-liter PEG (2 L PEG) plus ascorbic acid versus 4-liter PEG (4 L PEG). We performed a retrospective study on colonoscopy in patients with liver cirrhosis. Patients referred for colonoscopy were divided into 2 groups: 2 L PEG plus ascorbic acid (n = 105) and 4 L PEG (n = 61). Safety was assessed by comparing the clinical factors and laboratory findings as follows: blood biochemistry, electrolytes, weight change, and bowel-cleansing quality. Serum electrolytes, laboratory findings, and body weight showed no significant change between the 2 groups. There was no significant change in clinical factors before and after bowel preparation in the PEG group or the PEG plus ascorbic acid group. The acceptability and compliance of patients was better in the 2 L PEG plus ascorbic acid than the 4 L PEG group. In subgroup analysis, patients with compensated or decompensated cirrhosis showed no increased risk of electrolyte imbalances after bowel preparation. Child-Pugh scores did not influence the outcome after bowel cleansing. Successful cleansing was mostly achieved in both groups. Our analysis showed that of the use of 2 L PEG plus ascorbic acid could be a safe choice for colonoscopy in patients with liver cirrhosis.
PMID
Related Publications

Does 2 L Polyethylene Glycol Plus Ascorbic Acid Increase the Risk of Renal Impairment Compared to 4 L Polyethylene Glycol?

Efficacy of morning-only 4 liter sulfa free polyethylene glycol vs 2 liter polyethylene glycol with ascorbic acid for afternoon colonoscopy.

Randomized trial of 2-L polyethylene glycol + ascorbic acid versus 4-L polyethylene glycol as bowel cleansing for colonoscopy in an optimal setting.

A randomized controlled trial evaluating a new 2-L PEG solution plus ascorbic acid vs 4-L PEG for bowel cleansing prior to colonoscopy.

A meta-analysis of randomized controlled trials of low-volume polyethylene glycol plus ascorbic acid versus standard-volume polyethylene glycol solution as bowel preparations for colonoscopy.

Authors

Mayor MeshTerms

Liver Cirrhosis

Keywords
Journal Title medicine
Publication Year Start




PMID- 29390432
OWN - NLM
STAT- MEDLINE
DCOM- 20180213
LR  - 20180213
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 51
DP  - 2017 Dec
TI  - The safety and effectiveness of 2-liter polyethylene glycol plus ascorbic acid in
      patients with liver cirrhosis: A retrospective observational study.
PG  - e9011
LID - 10.1097/MD.0000000000009011 [doi]
AB  - The safety of bowel-cleansing agents is an important issue in clinical practice, 
      especially in patients with chronic diseases. Although the safety and efficacy of
      polyethylene glycol (PEG) has been investigated in many studies, few studies on
      PEG plus ascorbic acid exist. In this study, we compared the safety of 2
      bowel-cleansing agents for patients with liver cirrhosis: 2-liter PEG (2 L PEG)
      plus ascorbic acid versus 4-liter PEG (4 L PEG). We performed a retrospective
      study on colonoscopy in patients with liver cirrhosis. Patients referred for
      colonoscopy were divided into 2 groups: 2 L PEG plus ascorbic acid (n = 105) and 
      4 L PEG (n = 61). Safety was assessed by comparing the clinical factors and
      laboratory findings as follows: blood biochemistry, electrolytes, weight change, 
      and bowel-cleansing quality. Serum electrolytes, laboratory findings, and body
      weight showed no significant change between the 2 groups. There was no
      significant change in clinical factors before and after bowel preparation in the 
      PEG group or the PEG plus ascorbic acid group. The acceptability and compliance
      of patients was better in the 2 L PEG plus ascorbic acid than the 4 L PEG group. 
      In subgroup analysis, patients with compensated or decompensated cirrhosis showed
      no increased risk of electrolyte imbalances after bowel preparation. Child-Pugh
      scores did not influence the outcome after bowel cleansing. Successful cleansing 
      was mostly achieved in both groups. Our analysis showed that of the use of 2 L
      PEG plus ascorbic acid could be a safe choice for colonoscopy in patients with
      liver cirrhosis.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Lee, Jae Min
AU  - Lee JM
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine,
      Korea University College of Medicine, Seoul, Korea.
FAU - Lee, Jae Hyung
AU  - Lee JH
FAU - Kim, Eun Sun
AU  - Kim ES
FAU - Lee, Jung Min
AU  - Lee JM
FAU - Yoo, In Kyung
AU  - Yoo IK
FAU - Kim, Seung Han
AU  - Kim SH
FAU - Choi, Hyuk Soon
AU  - Choi HS
FAU - Keum, Bora
AU  - Keum B
FAU - Seo, Yeon Seok
AU  - Seo YS
FAU - Jeen, Yoon Tae
AU  - Jeen YT
FAU - Lee, Hong Sik
AU  - Lee HS
FAU - Chun, Hoon Jai
AU  - Chun HJ
FAU - Um, Soon Ho
AU  - Um SH
FAU - Kim, Chang Duck
AU  - Kim CD
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cathartics)
RN  - 30IQX730WE (Polyethylene Glycols)
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - AIM
SB  - IM
MH  - Ascorbic Acid/administration & dosage/adverse effects/*therapeutic use
MH  - Cathartics/administration & dosage/adverse effects/*therapeutic use
MH  - Colonoscopy
MH  - Female
MH  - Humans
MH  - *Liver Cirrhosis
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/administration & dosage/adverse effects/*therapeutic use
MH  - Retrospective Studies
PMC - PMC5758134
EDAT- 2018/02/03 06:00
MHDA- 2018/02/14 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
AID - 10.1097/MD.0000000000009011 [doi]
AID - 00005792-201712220-00019 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(51):e9011. doi: 10.1097/MD.0000000000009011.